Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights - AGEN

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Agenus Inc. for allegedly issuing false and misleading statements regarding the effectiveness of its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action lawsuit claims that the combination therapy of botensilimab and balstilimab was less effective than what was communicated to investors [1]. - The complaint alleges that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these misleading statements, the company's public disclosures were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action and may seek lead plaintiff status by the deadline of November 5, 2024 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].